EMEA-001585-PIP01-13-M03

Key facts

Active substance
Selumetinib
Therapeutic area
Oncology
Decision number
P/0279/2019
PIP number
EMEA-001585-PIP01-13-M03
Pharmaceutical form(s)
  • Age-appropriate oral dosage form
  • Capsule, hard
Condition(s) / indication(s)
  • Treatment of melanoma
  • Treatment of neurofibromatosis type 1
  • Treatment of thyroid cancer
Route(s) of administration
Oral use
Contact for public enquiries
AstraZeneca AB

E-mail: paediatrics@astrazeneca.com
Tel. +44 1625230700

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating